PRESS-RELEASE filed Mar 9, 2026 at 16:02 ET
Alpha Tau Medical reported its 2025 financial results, showing a wider net loss of $42.6 million ($0.53/share) compared to $31.8 million ($0.45/share) in 2024, driven by higher R&D and G&A expenses. Despite the increased loss, the company highlighted significant clinical and regulatory progress, including Japanese marketing approval for head and neck cancer, five U.S. trial approvals, and positive pancreatic cancer data presented at ASCO GI, while ending the year with $76.9 million in cash.